INTRODUCTION
Birt-Hogg-Dubé (BHD) syndrome is an autosomal, dominantly inherited, monogenic condition, characterized by the development of fibrofollicu lo mas (benign skin tumors) on the face, head and upper torso, pulmonary cysts and pneumothorax (co llapsed lung), and predisposition to kidney cancers with clear cell, chro mophobic or oncocytic features 1 . Birt-Hogg-Dubé syndrome affects the skin and increases the risk of certain types of tumors. The condition is characterized by mu ltip le noncancerous tumors of the hair follicles, particu larly on the face, neck, and upper chest. These growths typically first appear in a person's twenties or thirties. People with Birt-Hogg-Dubé syndrome also have an increased risk of developing cancerous or noncancerous kidney tumors (chromophobe renal cell carcino ma and oncocytoma, respectively) and possibly tumors in other organs and tissues. Additionally, affected individuals frequently develop cysts in the lungs that are at risk to rupture and cause an abnormal collect ion of air in the chest cavity (pneumothorax) that may result in the collapse of a lung. In 2001, a BHD-associated gene locus was localized to chromosome 17p 11.2 2, 3 and a novel gene, Folliculin (FLCN), was subsequently identified as being inactivated in individuals with BHD syndrome 4 .
BHD gene is also known as FLCN gene. This gene codes for a protein called Fo lliculin (FLCN), wh ich has a putative tumor suppressor function 5, 6, 7, 8 . FLCN is predicted to encode the 579 amino acid protein FLCN (64kDa) 9 . Fo lliculin naturally interacts with two proteins -Folliculin interacting protein 1(FNIP1) and Follicu lin interacting protein 2 (FNIP2) 10, 11, 12 . Binding of FLCN to FNIP1 and FNIP2 is mediated specifically through the Cterminal region of FLCN 10, 11, 12 . In BHD syndrome, the majority of mutations were predicted which introduces a premature stop codon into FLCN, and therefore result in a protein truncation 13 . However, it is presently unclear whether this truncated FLCN is targeted for nonsensemed iated decay, or remains in the cell with an altered function but these mutations remove the ability of FLCN to interact with FNIP1 and FNIP2, which suggests that this interaction is functionally important. Recently, Baba and colleagues identified a novel fo lliculin-interacting protein, FNIP1, by co-immunoprecipitation studies in mammalian cells. They found that FNIP1 binds to 5' -AMP activated protein kinase, a negative regulator of mTOR suggesting that folliculin and its interacting partner may be involved in the AMPK and mTOR signalling pathways 10 .
FLCN has an essential role in the regulation of Transforming Growth Factor-beta (TGF-β) signalling 6 . FLCN appears to regulate apoptosis through TGF -β-dependent transcription, which could help to further explain the renal cancer phenotype observed in BHD syndrome. In nut shell FLCN has been imp licated in numerous signalling pathways including mTOR and AMPK signalling 14, 10, 15 Hypoxia Inducible Factor (HIF) signalling 3 , TGF-β signalling 5, 6 and the JAK-STAT signalling pathway 16 . Mutation in FLCN gene increases activity of three other genes HIF1A, HIF2A, and TFE3 and cause proliferat ion of cell, a typical causative of cancer. According to research in past a disulfide co mpound KC7F2 shown to inhibit the proliferat ion of cancer cells and decreases Hypoxia Inducible Factor-1 Alpha (HIF-1A) levels by down regulating HIF-1A protein synthesis 17 .
ABS TRACT
Birt-Hogg-Dube´ (BHD) syndrome is an inherited and autosomal disease characterized by skin and kidney tumors, as well as cystic lung disease, which results from mutation in BHD gene / FLCN gene. The product of FLCN gene is folliculin protein which has been implicated in numerous signalling pathways like mTOR, AMPK signalling, HIF signalling, TGF-β signalling and the JAK-STAT signalling pathway. From literature it was clear that there were two major consequences of mutated folliculin. First is hindrance in formation of FLCN, FNIP1 and FNIP2 complex, which ultimately interacts with TGF-β protein of TGF-β signalling pathway and inactivates tumor suppression function of that pathway. The other major consequence is activation of HIF1A. From HIF-reporter cell-based screening studies of a natural product-like chemical library it is suggested that KC7F2 is an inhibitor of HIF1A. Thus here we have focused on another inducible factor HIF2A interaction with KC7F2 to carry out insilico analysis. A previous study also suggests ability of TSA to reverse the biological and molecular d efects of BHD cells but they have also suggested that further work will be needed to elucidate the nature of these effects. So we have carr ied out the work to study the nature of these effects and the mode of interaction between TSA and TGF-β protein. We found that TSA binds with TGF-β protein at same site where the non-mutated folliculin protein was binding and thus the TGF-β protein works normally, as a result anti-proliferation will takes place via p15 protein and ultimately the tumor suppression will takes place.
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Fro m literature it was clear that there were two major consequences takes place because of mutated follicu lin protein. First is hindrance in formation of FLCN, FNIP1 and FNIP2 co mplex which u ltimately interacts with TGF-β protein of TGF-β signalling pathway and inactivates tumor suppression function of that pathway. The other major consequence is activation of HIF1A. Fro m HIF -reporter cell-based screening studies of a natural product-like chemical library it is suggested that KC7F2 is an inhibitor of HIF1A 17 . Thus here we have focused on another inducible factor Hypo xia Inducible Factor-2 A lpha (HIF2A) interaction with KC7F2 to carry out in silico analysis. A previous study also suggests ability of TSA to reverse the biological and mo lecular defects of BHD cells but they have also suggested that further work will be needed to elucidate the nature of these effects. So we have carried out the work to study the nature of these effects and the mode of interaction between Trichostatin A (TSA) and TGF-β protein. We found that TSA binds with TGF-β protein at same site where the non-mutated follicu lin protein was binding and thus the TGF -β protein works normally as a result, anti-pro liferation will takes place via p15 protein and ultimately the tumor suppression will takes place. Understanding the structure as well as interaction will help in treat ment. In this study, we investigated structure of FLCN, interacting proteins and potential ligands which may help in overcoming fro m the BHDS.
MATERIALS AND METHODS

Sequence retrieval
The sequences of FLCN and HIF2A were retrieved fro m one of the largest sequence repository NCBI with sequence ID NP_ 659434.2 and NP_001421.2, respectively.
Protein Structure modeling & Vali dati on
Structure of TGF-β is obtained from the Protein Databank but structural search of FLCN and HIF2A proteins suggested that structures of both proteins were not present in Protein Databank (PDB). But we found the modeled structure of FLCN by using different template in Protein Model Portal. According our studies of Ramachandran plot of modeled fo lliculin protein by 2pziA we found that the ramachandran plot revealed 63.0% amino acids in favoured, 6.2% amino acids in allowed and 1.8% amino acids in generously allowed regions which can be improved by modeling the protein using other template. Thus template based modeling approach using Swiss -PDB Viewer (SPDBV) was applied to model the protein structure of FLCN. 2p 82 (Hu man cysteine protease ATG4A) template was used to model FLCN protein. Same template was used to model HIF2A as the sequence similarity was good between the HIF2A and 2p82. Further to check the quality of the modeled structure, structure verification server PROCHECK was utilized and analysis of molecular surface and binding cavities of different volume and area was done using SPDBV.
Ligand Finding
The ligand TSA for TGF-β is retrieved fro m Drug Bank with DB04297 (EXPT03123). Other suggested ligand KC7F2 for HIF2A was produced by MarvinSketch by using the basic information about it like IUPA C name and chemical formula fro m the literature survey as it was not present in any drug databases. It satisfied majority of all the Lip inski's rule of 5. 
Interaction studies
After identification of binding cavities and the appropriate putative ligand, protein-protein interaction and ligandreceptor interactions was done by using PATCHDOCK and FireDock server.
RES ULTS AND DISCUSS ION
The structures of protein FLCN and HIF2A were modeled by temp late based modeling using SPDBV tool. With the use of PDB specific BLAST appropriate template structure was searched which resulted in 6 template structures with less than 35% similarity were obtained. These 6 structures were used as a template but the structure modeled with these templates failed in structure validation by ramachandran plot. After this, GENE3D gave informat ion about the interacting protein partners of Follicu lin. Analysis of interacting proteins of follicu lin confirmed GA BARAP family and PRK family as its interacting partners. Both the above protein s tructures showed high sequence similarity with Folliculin (Sequence similarity: 54%, Query coverage: 21%) and were used as a template to model the folliculin protein. But data of model validation represented that folliculin modeled using PRKAA1 (pdb id: 2H6D), had ramachandran plot is only 22.3% wh ich represents a poor structure.
On the other hand by using GABARAP protein-cysteine protease ATG4A (pdb id: 2p 82), modeling of fo llicu lin show ramachandran plot which represents model of acceptable quality. Analysis of ramachandran plot revealed 88.4% in favoured, 8.4% in allo wed and 2.0% in generously allowed regions which is also better than the modeled structure available in the protein model portal. The modeled structure of folliculin (fig3) and HIF2A are deposited in international modeled protein structure repository named Protein model database (PMDB) with PMID: PM 0078009 and PM 0078067, respectively. The validation of modeled HIF2A protein through Ramachandran plot gave the following results i.e. 88.3% amino acids in favoured region, 8.9% amino acids in allo wed region and 1.8% amino acids in generously allo wed region.
The sole purpose of modeling the proteins were to study their interactions. The interactions are of TGF-β with FLCN and HIF2 with KC7F2, respectively. FLCN in its active form works as a tumor suppressor through TGF-β pathway but when FLCN is in inactive fo rm because of the mutation, it hinders TGF-β pathway and its normal function of tumor suppression. Therefore we focused on protein-protein interactions study of FLCN with TGF-β protein have tried to propose a putative ligand that can bind TGF-β at same binding pocket of FLCN and thus can reinforce the normal function of TGF-β as tumor suppressor. Val441 o f FLCN was interacted with ser73 of TGF-β and the bond length is 1.1A between them. The global energy of this interaction is -63.72 kcal/ mo l generated by FireDock. We have found ligand TSA, which is HDA C inhibitor and an organic compound used as an appropriate ligand to activate the TGF -β signalling pathway. We have to treat TGF-β protein with TSA to make the TGF-β signalling pathway normal functioning and thus it med iate tumor suppressor. 
TGF-β signalling pathway
TSA binds with TGF-β protein and then this will further binds with TGFβ R1. No w this complex will bind with smad2 and it phosphorylates smad2 by doing this the activity of p15 became active and the level of Bim proteins were increased. So, that the work of anti proliferation and pro apoptosis is done by p15 and Bim protein, respectively.
Ser73 o f TGF-β is interacting with TSA. The bond length between them is 0.4A . The global energy of this interaction is -44.70kcal/ mo l. TSA bound on the same amino acid where FLCN binds with TGFβ. Fro m this analysis, TSA can be considered as a drug to treat the BHDS syndrome. According to the natural function of FLCN it inhibits the activity of HIF2A protein. But because of mutation, FLCN became inactive and this protein became act ivated which is responsible for uncontrolled cell proliferation. Therefore it is required to inhibit this protein, as blocking of this protein will control the activity of cell proliferation. KC7F2 is a chemical drug which is used to block the hypoxia response (low o xygen tension). So, we have tried to use as a ligand to block the HIF2A protein.
Interaction of HIF2A with KC7F2 was performed (fig7). The interaction shows that Lys503 of HIF2A was interacted with KC7F2 with 0.4A bond length. And the global energy produced by FireDock result of this interaction is -60.69kcal/ mo l. 
CONCLUS ION
Fro m the present studies we can conclude that the function of follicu lin protein is to suppress formation of tu mor by different pathways. From pathway analysis, different reactions were studied to block the proliferat ion of the cells wh ich form tu mors. By p roviding the external drug like TSA, the process of phosphorylation of SMAD2 is done. It activates Bim protein and p15 protein which work as pro-apoptotic and anti-proliferat ive, respectively. HIF2A is blocked by KC7F2 treat ment. So by doing this, we may cure the disease. Further web lab analysis of this can be done for better understanding of the functioning of the suggested treatments. 
